VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ARGXargenx SE
$877.72$54.3B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksARGXPrice Target
ARGX logo

argenx SE (ARGX) Price Target Analysis

Updated Jun 18, 2026
Analyst Rating: Buy
Based on 36 analysts

29.5% Below Target

ARGX trades 29.5% below Wall Street's consensus target of $1136.83.

Current Price$877.72
Average Target$1136.83
Target
Current
Low$940.00
Median$1152.50
High$1291.00

Analyst Target Range

Forward P/E33.0x
(Growth Premium)
PEG Ratio—
Implied Growth+22.0%
(Moderate)
Analyst Spread30.9%
(Moderate)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$877.72
Consensus$1136.83
High$1291.00
Low$940.00

Consensus Scenario Assumptions

The base valuation assumes ARGX achieves its forward estimates and maintains a stable P/E multiple of 33.0x. This scenario reflects the blended consensus of 36 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 36 published analyst recommendations for ARGX

31/36 analysts are bullish
+44
BearishBullish
Weighted analyst sentiment score based on 36 ratings
ConsensusBuy
Coverage36 Analysts
Net Score+44
Bull / Bear86% / 0%
Strong Buy13%
Buy3083%
Hold514%
Sell00%
Strong Sell00%
Strong Buy
13%
Buy
3083%
Hold
514%
Sell
00%
Strong Sell
00%
Recommendation Mix86% Buy · 14% Hold · 0% Sell
Buy (31)Hold (5)Sell (0)

ARGX Price Target Analysis

Updated June 22, 2026

As of June 22, 2026, argenx SE (ARGX) has a Wall Street consensus price target of $1136.83, based on estimates from 36 covering analysts. With the stock currently trading at $877.72, this represents a potential upside of +29.5%. The company has a market capitalization of $54.32B.

Analyst price targets range from a low of $940.00 to a high of $1291.00, representing a 31% spread in expectations. The median target of $1152.50 aligns closely with the consensus average.

The current analyst consensus rating is Buy, with 31 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, ARGX trades at a trailing P/E of 44.7x and forward P/E of 33.0x. Analysts expect EPS to grow +22.0% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $1241.05, with bear and bull scenarios of $781.86 and $1635.21 respectively. Model confidence stands at 61/100, reflecting moderate uncertainty in projections.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+61.1%
Industry Consensus
Avg Forward P/E
23.4x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
RARE logo
RAREUltragenyx Pharmaceutical Inc.
$2.7B$27.44$48.36
+76.2%
Buy—33
ALNY logo
ALNYAlnylam Pharmaceuticals, Inc.
$37.1B$278.09$454.27
+63.4%
Buy37.1x52
SRPT logo
SRPTSarepta Therapeutics, Inc.
$1.9B$17.53$25.14
+43.4%
Buy5.0x54
BMRN logo
BMRNBioMarin Pharmaceutical Inc.
$10.5B$54.69$89.93
+64.4%
Buy11.1x41
IONS logo
IONSIonis Pharmaceuticals, Inc.
$12.2B$74.12$109.44
+47.7%
Buy—32
ACAD logo
ACADACADIA Pharmaceuticals Inc.
$3.7B$21.62$33.67
+55.7%
Buy55.6x37
IMVT logo
IMVTImmunovant, Inc.
$7.3B$35.34$45.00
+27.3%
Buy—23
ARDX logo
ARDXArdelyx, Inc.
$1.5B$6.05$17.00
+181.0%
Buy—16
VRTX logo
VRTXVertex Pharmaceuticals Incorporated
$114.9B$451.63$553.93
+22.7%
Buy23.4x56
HALO logo
HALOHalozyme Therapeutics, Inc.
$8.1B$68.55$88.25
+28.7%
Buy8.5x27

ARGX — Frequently Asked Questions

Quick answers to the most common questions about buying ARGX stock.

What is the ARGX stock price target for 2026?

The consensus Wall Street price target for ARGX is $1136.83, representing 29.5% upside from the current price of $877.72. With 36 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is ARGX a buy, sell, or hold?

ARGX has a consensus rating of "Buy" based on 36 Wall Street analysts. The rating breakdown is predominantly bullish, with 31 Buy/Strong Buy ratings. The consensus 12-month price target of $1136.83 implies 29.5% upside from current levels.

Is ARGX stock overvalued or undervalued?

ARGX trades at a forward P/E of 32.9602x, representing a moderate valuation. With analysts targeting $1136.83 (29.5% implied move), the stock appears reasonably valued with upside.

How high can ARGX stock go?

The most bullish Wall Street analyst has a price target of $1291 for ARGX, while the most conservative target is $940. The consensus of $1136.83 represents the median expectation. Our quantitative valuation model projects a bull case target of $1635 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover ARGX stock?

ARGX is heavily covered by Wall Street, with 36 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 30 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the ARGX stock forecast?

The 12-month ARGX stock forecast based on 36 Wall Street analysts shows a consensus price target of $1136.83, with estimates ranging from $940 (bear case) to $1291 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $1241, with bear/bull scenarios of $782/$1635.

What is ARGX's fair value based on fundamentals?

Our quantitative valuation model calculates ARGX's fair value at $1241 (base case), with a bear case of $782 and bull case of $1635. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 61/100.

What is ARGX's forward P/E ratio?

ARGX trades at a forward P/E ratio of 33.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 44.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy ARGX stock?

Wall Street analysts are very optimistic on ARGX, with a "Buy" consensus rating and $1136.83 price target (29.5% upside). 31 of 36 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do ARGX price targets vary so much?

ARGX analyst price targets range from $940 to $1291, a 31% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $1136.83 consensus represents the middle ground. Our model's $782-$1635 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into ARGX consensus models and risk factors.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare